Suzanne Ransehousen
Gerontology · Hockessin, DENPI 1255323556
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations.
Across 29 payments — averaging $74.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$358
- Neurocrine Biosciences, Inc.$326
- Otsuka America Pharmaceutical, Inc.$207
- Acadia Pharmaceuticals Inc$163
- Sun Pharmaceutical Industries Inc.$142
- Fresenius USA Marketing, Inc.$125
- plus $853 from 11 others
What the payments were for
- Food & beverage$2,174100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $358 |
| Neurocrine Biosciences, Inc. | 4 | $326 |
| Otsuka America Pharmaceutical, Inc. | 3 | $207 |
| Acadia Pharmaceuticals Inc | 5 | $163 |
| Sun Pharmaceutical Industries Inc. | 1 | $142 |
| Fresenius USA Marketing, Inc. | 1 | $125 |
| Novo Nordisk | 1 | $125 |
| GSK | 1 | $123 |
| Boston Scientific | 1 | $101 |
| Teva Pharmaceuticals USA, Inc. | 1 | $100 |
| Cipher Pharmaceuticals US LLC | 1 | $99 |
| E.r. Squibb & Sons, L.L.C. | 1 | $88 |
| Inspire Medical Systems, Inc. | 1 | $85 |
| Merck | 1 | $79 |
| Sunovion Pharmaceuticals Inc. | 1 | $26 |
| Pfizer | 1 | $14 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DRIZALMA SPRINKLE$142
- Ozempic$125
- Velphoro$125
- AREXVY$123
- Watchman$101
How this compares
Too few gerontology providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 165 | $103,087 |
| XareltoRivaroxaban | 65 | $51,281 |
| JanuviaSitagliptin Phosphate | 50 | $31,959 |
| TrulicityDulaglutide | 68 | $30,805 |
| OzempicSemaglutide | 24 | $28,664 |
| RexultiBrexpiprazole | 12 | $11,168 |
| RestasisCyclosporine | 14 | $7,810 |
| MyrbetriqMirabegron | 12 | $6,512 |
| Escitalopram Oxalate | 273 | $5,330 |
| Gabapentin | 222 | $5,024 |
| Budesonide | 19 | $4,798 |
| Atorvastatin Calcium | 281 | $4,646 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $4,551 |
| Levothyroxine Sodium | 339 | $4,478 |
| Duloxetine Hcl | 92 | $4,110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $103,087165 claims |
| MerckJanuvia | $79 | $31,95950 claims |
| Novo NordiskOzempic | $125 | $28,66424 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $207 | $11,16812 claims |
| GSKAnoro Ellipta, Arexvy | $123 | $8,60325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gerontology providers in Delawareon file to place this against a meaningful peer group, so we don't.
Other gerontology in Hockessin
- Love JonesHockessin$105
- Svetlana AgapovLewes$3K
- Maria AshWilmington$1K
- Jennifer EntrekinNewark$842
- Lauren PiascinskiNewark$827
- Carla HullMilford$804
- Adrienne BriggsDover$564
- Denise LyonsNewark$226
- Debra LynchMiddletown$148
- Elizabeth NzomoLewes$92
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.